For research use only. Not for therapeutic Use.
Olomoucine（Cat No.:R003265）is a selective cyclin-dependent kinase (CDK) inhibitor, primarily targeting CDK1, CDK2, and CDK5. It disrupts cell cycle progression by inhibiting CDK activity, which plays a crucial role in regulating cell division and proliferation. Olomoucine has been widely studied for its potential in cancer research, where it induces cell cycle arrest and apoptosis in rapidly dividing cells. Additionally, it has been used to explore neuroprotective effects due to its ability to inhibit CDK5, which is implicated in neurodegenerative diseases. Olomoucine remains a valuable tool in cell cycle and cancer biology research.
| Catalog Number | R003265 |
| CAS Number | 101622-51-9 |
| Synonyms | N2-[(2-Hydroxyethyl)-N6-benzyladenine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; NSC 666096; |
| Molecular Formula | C15H18N6O |
| Purity | ≥95% |
| Target | Cyclin-Dependent Kinases |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol |
| InChI | InChI=1S/C15H18N6O/c1-21-10-18-12-13(17-9-11-5-3-2-4-6-11)19-15(16-7-8-22)20-14(12)21/h2-6,10,22H,7-9H2,1H3,(H2,16,17,19,20) |
| InChIKey | GTVPOLSIJWJJNY-UHFFFAOYSA-N |
| SMILES | CN1C=NC2=C(N=C(N=C21)NCCO)NCC3=CC=CC=C3 |
| Reference | </br>1:Down-regulation of BNIP3 by olomoucine, a CDK inhibitor, reduces LPS- and NO-induced cell death in BV2 microglial cells. Tsou YC, Wang HH, Hsieh CC, Sun KH, Sun GH, Jhou RS, Lin TI, Lu SY, Liu HY, Tang SJ.Neurosci Lett. 2016 Aug 15;628:186-93. doi: 10.1016/j.neulet.2016.06.040. Epub 2016 Jun 21. PMID: 27345388 </br>2:Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs). Hofman J, Kučera R, Neumanova Z, Klimes J, Ceckova M, Staud F.Xenobiotica. 2016;46(5):416-23. doi: 10.3109/00498254.2015.1086039. Epub 2015 Sep 12. PMID: 26364927 </br>3:Synergistic actions of olomoucine and bone morphogenetic protein-4 in axonal repair after acute spinal cord contusion. Chen L, Li J, Wu L, Yang M, Gao F, Yuan L.Neural Regen Res. 2014 Oct 15;9(20):1830-8. doi: 10.4103/1673-5374.143431. PMID: 25422646 Free PMC Article</br>4:Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. Cihalova D, Hofman J, Ceckova M, Staud F.PLoS One. 2013 Dec 23;8(12):e83467. doi: 10.1371/journal.pone.0083467. eCollection 2013. PMID: 24376706 Free PMC Article</br>5:Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). Hofman J, Kučera R, Cihalova D, Klimes J, Ceckova M, Staud F.PLoS One. 2013 Oct 8;8(10):e75520. doi: 10.1371/journal.pone.0075520. eCollection 2013. PMID: 24116053 Free PMC Article</br>6:Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Hofman J, Ahmadimoghaddam D, Hahnova L, Pavek P, Ceckova M, Staud F.Pharmacol Res. 2012 Mar;65(3):312-9. doi: 10.1016/j.phrs.2011.11.017. Epub 2011 Dec 6. PMID: 22173067 </br>7:The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors. Korinkova G, Cwiertka K, Paprskarova M, Dzubak P, Hajduch M.Neoplasma. 2010;57(2):161-9. PMID: 20099981 </br>8:The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, Hrstka R, Krystof V, Strnad M, Vojtesek B.Antivir Chem Chemother. 2010 Jan 5;20(3):133-42. doi: 10.3851/IMP1460. PMID: 20054100 Free PMC Article</br>9:Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis. Małecki JM, Bentke A, Ostrowska B, Laidler P.Melanoma Res. 2010 Feb;20(1):52-8. doi: 10.1097/CMR.0b013e328332f1e6. PMID: 20010439 </br>10:Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Wandl S, Wesierska-Gadek J.Ann N Y Acad Sci. 2009 Aug;1171:242-9. doi: 10.1111/j.1749-6632.2009.04700.x. PMID: 19723061 |
